Nervous System News and Research

Latest Nervous System News and Research

AANS: Accidental falls are leading cause of non-fatal injury among Americans of all ages

Accidental falls are the leading cause of non-fatal injury among Americans of all ages according to the American Association of Neurological Surgeons (AANS). And among Americans age 65 and older, falls are the leading cause of fatal injuries. Among older adults, traumatic brain injury (TBI) causes nearly 50 percent of fall-related fatalities.

10 Feb 2010

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

In an aging society, falling is a growing problem. Just one bad fall can mark the start of a downward spiral in an older person's health and quality of life. The cost of treating falls also puts a heavy burden on the health care system. Toronto Rehab scientists have developed a simple footwear insole called SoleSensor(TM), which has proven to improve balance and prevent falls.

10 Feb 2010

APA releases proposed draft diagnostic criteria for DSM-5

The American Psychiatric Association today released the proposed draft diagnostic criteria for the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM). The draft criteria represent content changes under consideration for DSM, which is the standard classification of mental disorders used by mental health and other health professionals, and is used for diagnostic and research purposes.

10 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010

Drinking milk during pregnancy can protect baby against multiple sclerosis

Drinking milk during pregnancy may help reduce your baby's chances of developing multiple sclerosis (MS) as an adult, according to a preliminary study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

Third-quarter fiscal 2010 results announced by Clinical Data

Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.

9 Feb 2010

Lundbeck launches web-based initiative to support people with rare diseases

In support of Rare Disease Day 2010, set for February 28, Lundbeck Inc. today launched the Raise Your Hand to Fight Rare Diseases campaign. The web-based initiative is designed to generate support for people with rare diseases and is being conducted in partnership with the National Organization for Rare Disorders (NORD), the sponsor of Rare Disease Day in the United States.

9 Feb 2010

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months.

9 Feb 2010

Mediterranean diet can avoid brain infarcts, reduce risk of Alzheimer's disease

A Mediterranean diet may help people avoid the small areas of brain damage that can lead to problems with thinking and memory, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

9 Feb 2010

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer’s disease and other neurodegenerative conditions.

9 Feb 2010

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.

9 Feb 2010

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

9 Feb 2010

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

Workers exposed to TCE may be at higher risk of developing Parkinson's disease

Workers exposed to tricholorethylene (TCE), a chemical once widely used to clean metal such as auto parts, may be at a significantly higher risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

7 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

Study sheds new light on cancer metastasis

Some cells are natural rule-breakers. Neural crest cells for example, not only migrate throughout the body during development (most cells are more selective in their wandering), they are also more developmentally flexible than their predecessors (a no-no for nearly all cell types).

4 Feb 2010

Immigrants may be healthier than long-term residents

New immigrants to North America may be less likely to have a stroke at a young age than long-time residents, according to a study published in the February 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Nervous System News and Research

Latest Nervous System News and Research

AANS: Accidental falls are leading cause of non-fatal injury among Americans of all ages

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

APA releases proposed draft diagnostic criteria for DSM-5

TI commences Phase IIa clinical trial for its lead molecule in CDH

Drinking milk during pregnancy can protect baby against multiple sclerosis

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Third-quarter fiscal 2010 results announced by Clinical Data

Lundbeck launches web-based initiative to support people with rare diseases

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Mediterranean diet can avoid brain infarcts, reduce risk of Alzheimer's disease

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

AMRI announces fourth-quarter and full-year 2009 results

Workers exposed to TCE may be at higher risk of developing Parkinson's disease

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Study sheds new light on cancer metastasis

Immigrants may be healthier than long-term residents

Study: Generic nifedipine product not bioequivalent to Adalat XL

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in